Rhodococcus equi, a gram-positive facultative intracellular bacterium, is a common pulmonary pathogen in young horses and an emerging opportunistic pathogen in humans with AIDS (7, 25) . In young horses, R. equi causes a chronic pyogranulomatous pneumonia and rare cases of enteritis and osteomyelitis (25, 39) . In immunodeficient humans, disease is insidious and causes a severe, often fatal cavitary pneumonia similar to that caused by Mycobacterium tuberculosis (16, 32, 34, 37) . Although not currently targeted as an AIDS opportunistic infection, the number of R. equi pneumonia cases reported in AIDS patients is increasing (1, 3, 6, 10-12, 15, 26, 34, 35, 37) . In immunodeficient humans and animals, antibiotic therapy can reduce R. equi numbers but cannot effect clearance of the bacteria (11, 21) . Consequently, human AIDS patients infected with R. equi frequently have relapses requiring life-long therapy (11, 12, 26, 37) . Similarly, single and combination antibiotic therapy in experimentally infected nude mice, which lack T cells, does not effect clearance of R. equi (21) . Therefore, identification of the host immune mechanisms that mediate clearance of R. equi from the lungs would provide a basis for appropriate adjunct immunotherapy.
Functional T lymphocytes are required for pulmonary clearance of R. equi. Immunocompetent humans rarely develop R. equi infection; however, AIDS patients with low CD4 ϩ T-cell counts have an increased incidence of severe rhodococcal pneumonia (7) . Experimentally, immunocompetent mice effectively clear virulent R. equi infection (20, 40) . However, Tand B-cell-deficient severe combined immunodeficient (SCID) and T-cell-deficient athymic nude mice are unable to clear the organism (4, 20, 23, 30, 40) . In addition, adoptive transfer of immune spleen cells to irradiated mice followed by intravenous challenge decreases bacterial numbers significantly, whereas passive transfer of immune serum is not protective (23) . Recently, the role of CD4 ϩ and CD8 ϩ T-cell subsets in the clearance of R. equi was investigated. Partial depletion of both CD4 ϩ and CD8 ϩ T-cell subsets results in higher numbers of bacteria recovered from tissues 11 days following intravenous inoculation (23) . Following aerosol challenge, transgenic class I deficient mice, which lack functional CD8 ϩ T cells, clear R. equi from the lungs, while infection persists in transgenic class II deficient mice, which lack functional CD4 ϩ T cells (13 ϩ T cells are important in pulmonary clearance of Bordetella pertussis (17) . Specifically, adoptive transfer of immune CD4
ϩ T cells to athymic nude mice followed by respiratory B. pertussis challenge results in clearance of the bacteria. In addition, gamma interferon (IFN-␥) is expressed from immune spleen cells stimulated with B. pertussis antigen, suggesting a role for the Th1 subpopulation of CD4 ϩ T cells in pulmonary clearance (17) . The role of Th1 and Th2 cell-associated cytokines in pulmonary clearance of R. equi is unknown. A previous study has shown that partial neutralization of IFN-␥ and tumor necrosis factor alpha in mice infected intravenously with R. equi results in higher numbers of bacteria recovered from tissues early in the infection; however, the role of Th1 and Th2 cytokines in pulmonary clearance of R. equi has not been evaluated (22) . In this study, we used an intratracheal infection model in immunocompetent mice treated with anticytokine antibodies to examine the role of Th1-and Th2-specific cytokines in the clearance of pulmonary R. equi infections.
MATERIALS AND METHODS
Bacteria. R. equi ATCC 33701 is a virulent strain that possesses the 82-kb plasmid and expresses the 15-to 17-kDa proteins associated with virulence in mice (29, 31, 33) . The presence of the virulence-associated plasmid and proteins was confirmed by agarose gel electrophoresis and immunoblotting, respectively, as previously described (13) . Bacteria were maintained at Ϫ70ЊC prior to use.
Mice. Eight-week-old, female BALB/c (H-2 d ) mice were purchased from B & K Universal Inc. (Fremont, Calif.) and maintained in microisolator cages.
Antibodies. A hybridoma producing rat anti-mouse immunoglobulin G1 (IgG1) neutralizing monoclonal antibody (MAb) against IFN-␥ (MAb XMG6) was obtained from Alan Sher (National Institutes of Health, Bethesda, Md.) (5, 9) . A hybridoma producing an isotype control MAb (Y13-259) was obtained from the American Type Culture Collection. Purified 11B.11 MAb, which neutralizes murine interleukin-4 (IL-4), was provided by the National Cancer Institute Biological Response Modifiers Program (Frederick, Md.) (24) . The specificity of each MAb was confirmed by depletion of known concentrations of either IFN-␥ or IL-4. Briefly, 1 g of each antibody was incubated separately with 3,000 pg of IFN-␥ (Endogen, Inc., Boston, Mass.) or 75 pg of IL-4 (Endogen, Inc.) per ml for 30 min at 4ЊC. Antigen-antibody complexes were incubated with 50 l of protein G-Sepharose CL-6B for 15 min at 4ЊC and precipitated by centrifugation. The supernatant was assayed for the presence of remaining IFN-␥ or IL-4 by enzyme-linked immunosorbent assay (ELISA) (Endogen, Inc.), and absorbance was measured at 450 nm on an ELISA plate reader. IFN-␥ and IL-4 concentrations were depleted to undetectable levels (Ͻ5 pg) with MAbs XMG6 and 11B.11, respectively.
Intratracheal infection and antibody treatment. In each experiment, mice were assigned to three groups and treated intraperitoneally every 5 days with antibody. In the first experiment, three groups of mice were treated as follows: group 1, 2 mg of anti-IFN-␥ MAb; group 2, 2 mg of anti-IL-4 MAb; and group 3, 2 mg of isotype control MAb. In the second experiment, the treatment of group 1 remained unchanged, while groups 2 and 3 were treated with 5 mg of anti-IL-4 MAb or 5 mg of isotype control MAb, respectively. Four hours following the initial MAb treatment, mice from each group were anesthetized with intraperitoneal ketamine and xylazine and inoculated intratracheally with 2 ϫ 10 7 R. equi ATCC 33701. Enumeration of R. equi in the lungs. Lungs were collected and weighed aseptically, homogenized, and serially diluted on modified selective TSA medium to determine the number of CFU as described previously (38) . Briefly, lungs were minced in 1.0 ml of sterile phosphate-buffered saline (PBS) and homogenized in a laboratory stomacher for 30 s. Tissue homogenates were serially diluted on modified selective TSA medium and incubated for 48 h at 37ЊC to determine the number of CFU.
Isolation of CD4 ؉ T lymphocytes. CD4 ϩ T cells were isolated from bronchial lymph nodes by selective removal of CD8 ϩ T cells with a combination of rat anti-mouse CD8 MAb 2.43 and sheep anti-rat Ig magnetic beads followed by exposure to a magnetic field (14) . Briefly, bronchial lymph nodes were collected aseptically in Hanks' balanced salt solution (pH 7.2), and the cells were separated by gentle teasing with thumb forceps. The cells were washed twice, counted, and incubated with MAb 2.43, which binds CD8 ϩ T cells, for 30 min at 4ЊC. After being washed, the cells were incubated with M-450 sheep anti-rat IgG magnetic beads (Dynal) for 30 min at 4ЊC. Following exposure to a magnetic field, the remaining T cells (predominantly CD4 ϩ T cells) were collected in the supernatant. CD4 ϩ T-cell purity was determined, in two mice per group, by flow cytometric analysis (FACScan; Becton Dickinson). Surface-bound MAbs GK1.5, 2.43, B220, and M1/70.15, which recognize CD4 ϩ T cells, CD8 ϩ T cells, B cells, and macrophages, respectively, were detected with fluorescein isothiocyanatelabeled mouse anti-rat IgG.
RNA isolation and PCR analysis. IFN-␥ and IL-4 mRNA expression was evaluated by reverse transcriptase-PCR (RT-PCR). Total RNA was prepared from purified CD4 ϩ T cells by guanidine isothiocyanate lysis. Briefly, 2 ϫ 10 6 cells were homogenized in 8.5 ml of cold 4 M guanidine isothiocyanate buffer, layered onto 3 ml of RNase-free 5.7 M cesium chloride buffer, and centrifuged overnight. RNA was resuspended in 0.3 M sodium acetate (pH 6.0), incubated at 65ЊC for 10 min, and precipitated overnight with 2 volumes of absolute ethanol at Ϫ20ЊC. Pellets were washed with 70% ethanol, air dried, and resuspended in RNase-free water, and the RNA was quantitated spectrophotometrically. Firststrand cDNA was synthesized by using 1 g of total RNA, RT, and oligo(dT) primer in a final volume of 20 l at 42ЊC for 15 min. The products obtained were heat denatured, and 5 l was used for amplification with specific primers for IFN-␥, IL-4, and ␤-actin (Clontech Inc., Palo Alto, Calif. agarose gel and detected by ethidium bromide staining. At 3 days postinfection, samples were also amplified in the presence of a nonhomologous cDNA fragment (mimic) of either IFN-␥ (500 bp) or IL-4 (600 bp) for competitive-inhibition PCR (Clontech Inc.) (28, 36) . Preparation of lungs for light microscopy. Lungs from two mice per group were infused and fixed in 10% Formalin, embedded in paraffin wax, sectioned, and then stained with hematoxylin-eosin for histological examination.
Statistics. Significant differences between groups were identified by using a Mann-Whitney rank sum test after the overall model was determined to be significant with a Kruskal-Wallis nonparametric one-way analysis of variance.
RESULTS
Effect of anticytokine treatment on clearance of R. equi from the lungs. Mice were treated with different concentrations of anticytokine antibodies in two independent experiments to determine the importance of endogenous production of Th1-and Th2-specific cytokines in pulmonary clearance of R. equi. Five mice from each group were killed, and bacterial clearance was determined at 3 and 14 days postinfection in the first experiment and at 14 and 21 days postinfection in the second experiment. Mice treated with 2 mg of anti-IFN-␥ antibody had significantly (P Ͻ 0.05) more bacteria recovered from the lung at both 3 days (Fig. 1 ) and 14 days (data not shown) postinfection compared with mice treated with 2 mg of anti-IL-4 antibody or isotype control antibody. Similarly, mice treated with 2 mg of anti-IFN-␥ antibody had significantly (P Ͻ 0.05) more bacteria recovered from the lungs at 14 and 21 days postinfection than mice treated with 5 mg of anti-IL-4 antibody or isotype control antibody (Fig. 1) . All mice treated with 5 mg of anti-IL-4 antibody or isotype control antibody cleared pulmonary R. equi infection by 21 days (Fig. 1) .
Transcriptional analysis of bronchial lymph node CD4 ؉ T cells. To determine if anti-IFN-␥ or anti-IL-4 antibody treatment resulted in downregulation of IFN-␥ or IL-4, respectively, mRNA expression from bronchial lymph node CD4 ϩ T cells was analyzed by RT-PCR. CD4 ϩ T-cell purity was determined by flow cytometric analysis and ranged from 89 to 96% CD4 ϩ T cells, with Ͻ3% CD8 ϩ T cells. At 3 days postinfection, all mice expressed detectable levels of IFN-␥ and IL-4, as detected by agarose gel electrophoresis of PCR products, followed by ethidium bromide staining (data not shown). Consequently, to detect differences in IFN-␥ and IL-4 transcription at 3 days postinfection, mRNA expression was compared by Fig. 2) antibody, compared with mice treated with the isotype control antibody (Fig. 2) . At 21 days postinfection, IFN-␥ mRNA was still not detectable in mice treated with anti-IFN-␥ antibody (Fig. 3) . Mice treated with anti-IL-4 or isotype control antibodies had cleared infection by 21 days postinfection, and therefore, expression of IFN-␥ mRNA in bronchial lymph node CD4 ϩ T cells was at low levels ( Fig. 3) . In contrast, IL-4 mRNA expression was increased in all mice treated with anti-IFN-␥ antibody compared with isotype controls at either 14 days (Fig.  2) or 21 days (Fig. 3) postinfection.
Pathology of mouse lungs. All lungs were evaluated immediately after death to determine if R. equi infection resulted in pneumonia in the three treatment groups. Mice treated every 5 days with anti-IFN-␥ antibody developed variably sized multifocal pulmonary granulomas by 14 days postinfection (data not shown), which progressively enlarged and often obliterated entire lung lobes by 21 days postinfection (Fig. 4) . In contrast, lungs from mice treated with either 2 mg (data not shown) or 5 mg of anti-IL-4 antibody (Fig. 4) or isotype control antibody (data not shown) were normal.
Histopathology of mouse lungs. Lungs were evaluated from two mice per group at 14 and 21 days postinfection. Mice treated every 5 days with anti-IFN-␥ antibody developed multiple pulmonary granulomas by 21 days postinfection (Fig. 5b) . In contrast, mice treated with either 2 or 5 mg of anti-IL-4 antibody (Fig. 5a ) or isotype control antibody completely cleared the pulmonary infection by 21 days postinfection and did not have pulmonary lesions. Pulmonary granulomas were characterized by a large influx of eosinophils (Fig. 5c, arrow) , lymphocytes, alveolar macrophages, and multinucleate giant cells. Many alveolar macrophages and multinucleate giant cells had intracellular R. equi.
DISCUSSION
The results of this study demonstrate the importance of IFN-␥ in the clearance of R. equi from the lung. Using a direct intratracheal inoculation model, we have shown that neutralization of IFN-␥ in immunocompetent mice results in failure to clear pulmonary R. equi infection. Additionally, failure to clear pulmonary infection leads to the development of granulomas in the lung similar to those seen in natural R. equi infections of young horses and immunodeficient humans (25) . We have previously demonstrated that pulmonary clearance of R. equi is dependent on functional CD4 ϩ T cells (13) . Here, we show specifically that IFN-␥ expression is necessary for effective pulmonary clearance of R. equi. Although IFN-␥ expression from CD8 ϩ T cells or natural killer cells may contribute to clearance of intracellular pathogens, both CD4 ϩ T cells and IFN-␥ appear to be required for complete clearance of primary pulmonary infections with R. equi (8, 13) . Neutralization of endogenous IFN-␥ in immunocompetent BALB/c mice resulted in altered host resistance to R. equi and shifted the cytokine response from a predominantly Th1-like response to a predominantly Th2-like response, similar to that reported for Leishmania major-infected C57BL/6 and C3H/ HeN mice (2, 27) . Murine Th1 cells are defined by expression of IFN-␥, IL-2, and tumor necrosis factor beta and are reciprocally regulated by IL-4-, IL-5-, and IL-10-expressing Th2 cells (18) . In addition, IL-4 is required for the development of tissue eosinophilia, which is also dependent on expression of IL-5 (14) . In this study, mice treated with anti-IFN-␥ MAb failed to clear pulmonary infection, developed multiple pulmonary granulomas with large numbers of eosinophils, failed to express detectable IFN-␥ mRNA, and expressed increased IL-4 mRNA. The predominance of eosinophils in pulmonary granulomas and the enhanced IL-4 mRNA expression in bronchial lymph node CD4 ϩ T cells suggest the local development of a nonprotective Th2 response to R. equi infection following neutralization of IFN-␥. Both immunocompetent mice, which clear pulmonary R. equi by 21 days postinfection, and SCID mice, which remain persistently infected, do not develop pulmonary granulomas and consistently survive rhodococcal pneumonia. Here we demonstrated that neutralization of IFN-␥ in immunocompetent mice prior to intratracheal inoculation of R. equi results in pneumonia characterized by development of pulmonary granulomas. In addition, mice begin to die of severe granulomatous R. equi pneumonia by 26 days postinfection (data not shown). Therefore, development of pulmonary granulomas may depend on upregulation of Th2 cytokines or downregulation of Th1 cytokines.
Pulmonary clearance of R. equi is associated with increased bronchial lymph node CD4 ϩ T-cell expression of IFN-␥. Although these results suggest a role for CD4 ϩ Th1 cells in clearance of pulmonary R. equi infections, adoptive transfer of R. equi-specific Th1 cell lines may more clearly define the role of CD4 ϩ Th1 cells in host immunity to R. equi. Defining the immune mechanisms required to clear pulmonary R. equi infections is critical in identifying potential immunotherapeutic agents for the treatment of naturally occurring R. equi pneumonia in both young horses and human AIDS patients. Currently, few antibiotics are effective in treating established pulmonary R. equi infections in young horses. In addition, antibiotic treatment of rhodococcal pneumonia in immunodeficient humans requires extended, often life-long, therapy. Recently, the immunoregulatory cytokine IL-12, which drives development of Th1 cells and stimulates IFN-␥ production, demonstrated therapeutic activity in an established visceral Leishmania donovani infection in mice (19) . Therefore, if Th1 CD4 ϩ T cells are critical for pulmonary clearance of R. equi, upregulation of Th1 cells by induction of IL-12 or direct activation of macrophages with IFN-␥ may form the basis for immunotherapy.
